ANDREA RUPE: Open Payments
NPI 1942430335 · GALAX, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,202 in 120 payments from 25 companies in 2025. Trend: 2023 $2,768 · 2024 $2,119 · 2025 $2,202
Food & beverage: $2,202
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $256 |
| Novo Nordisk Inc | 14 | $225 |
| AstraZeneca Pharmaceuticals LP | 9 | $214 |
| Lilly USA, LLC | 10 | $196 |
| ABBVIE INC. | 13 | $153 |
| Amgen Inc. | 8 | $129 |
| Lundbeck LLC | 6 | $124 |
| Otsuka America Pharmaceutical, Inc. | 5 | $101 |
| Abbott Laboratories | 5 | $98 |
| PFIZER INC. | 5 | $82 |
Products named: CAPLYTA, REXULTI, MOUNJARO, Ozempic, FARXIGA, VRAYLAR, FREESTYLE LIBRE 3, OTEZLA.
Industry payments across VA — which companies pay providers there.
